疟疾及人口学因素对心电图QT间期的影响:个体患者数据的系统综述与荟萃分析
该研究系统检索并荟萃分析43项研究的10452例个体数据,采用贝叶斯分层多变量回归评估疟疾及人口学因素对治疗前QT间期的影响。结果显示,无并发症恶性疟患者QT间期较健康对照缩短61.77毫秒,重症疟疾缩短110.89毫秒,体温每升高1°C独立关联QT缩短2.80毫秒。结论提示需校正疟疾和退热相关的QT延长,以避免将疟疾相关QT变化误归因于抗疟药。
要点
- 无并发症恶性疟患者治疗前QT间期较健康对照缩短61.77毫秒。
- 重症疟疾患者QT间期缩短更显著,达110.89毫秒。
- 体温每升高1°C,QT间期独立缩短2.80毫秒。
核心结论
- 疟疾和退热过程可导致QT间期缩短,需校正以避免误判抗疟药心脏毒性。
研究设计与样本
- 系统综述与个体患者数据荟萃分析,纳入43项研究共10452人(疟疾患者9778例,健康对照674例)。
- 采用贝叶斯分层多变量回归与广义可加模型分析治疗前QT间期的影响因素。
主要发现
- 与健康对照相比,无并发症恶性疟患者QT间期缩短61.77毫秒(95%CI -80.71至-42.83)。
- 重症疟疾患者QT间期缩短110.89毫秒(95%CI -140.38至-81.25)。
- 体温每升高1°C,QT间期独立缩短2.80毫秒(95%CI -3.17至-2.42)。
- 疟疾患者QT间期对心率变化的敏感性增加。
关键数值与推荐
- 无并发症恶性疟QT间期较健康对照缩短61.77毫秒(95%CI -80.71至-42.83)。
- 重症疟疾QT间期缩短110.89毫秒(95%CI -140.38至-81.25)。
- 体温每升高1°C,QT间期缩短2.80毫秒(95%CI -3.17至-2.42)。
临床怎么用
- 评估抗疟药心脏毒性时需校正疟疾和发热恢复相关的QT变化。
- 对伴有发热的其他疾病使用延长QT间期药物时,可考虑类似校正。
局限性
- 无法评估疟疾临床试验中未常规收集的其他QT间期影响因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Electrocardiographic QT interval prolongation is the most widely used risk marker for ventricular arrhythmia potential and thus an important component of drug cardiotoxicity assessments. Several antimalarial medicines are associated with QT interval prolongation. However, interpretation of electrocardiographic changes is confounded by the coincidence of peak antimalarial drug concentrations with recovery from malaria. We therefore reviewed all available data to characterise the effects of malaria disease and demographic factors on the QT interval in order to improve assessment of electrocardiographic changes in the treatment and prevention of malaria. METHODS AND FINDINGS: We conducted a systematic review and meta-analysis of individual patient data. We searched clinical bibliographic databases (last on August 21, 2017) for studies of the quinoline and structurally related antimalarials for malaria-related indications in human participants in which electrocardiograms were systematically recorded. Unpublished studies were identified by the World Health Organization (WHO) Evidence Review Group (ERG) on the Cardiotoxicity of Antimalarials. Risk of bias was assessed using the Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (PROTECT) checklist for adverse drug events. Bayesian hierarchical multivariable regression with generalised additive models was used to investigate the effects of malaria and demographic factors on the pretreatment QT interval. The meta-analysis included 10,452 individuals (9,778 malaria patients, including 343 with severe disease, and 674 healthy participants) from 43 studies. 7,170 (68.6%) had fever (body temperature ≥ 37.5°C), and none developed ventricular arrhythmia after antimalarial treatment. Compared to healthy participants, patients with uncomplicated falciparum malaria had shorter QT intervals (-61.77 milliseconds; 95% credible interval [CI]: -80.71 to -42.83) and increased sensitivity of the QT interval to heart rate changes. These effects were greater in severe malaria (-110.89 milliseconds; 95% CI: -140.38 to -81.25). Body temperature was associated independently with clinically significant QT shortening of 2.80 milliseconds (95% CI: -3.17 to -2.42) per 1°C increase. Study limitations include that it was not possible to assess the effect of other factors that may affect the QT interval but are not consistently collected in malaria clinical trials. CONCLUSIONS: Adjustment for malaria and fever-recovery-related QT lengthening is necessary to avoid misattributing malaria-disease-related QT changes to antimalarial drug effects. This would improve risk assessments of antimalarial-related cardiotoxicity in clinical research and practice. Similar adjustments may be indicated for other febrile illnesses for which QT-interval-prolonging medications are important therapeutic options.
引用
- Chan XHS, Win YN, Haeusler IL, et al. Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data. PLoS Med. 2020. PMID: 32134952. doi:10.1371/journal.pmed.1003040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。